deltatrials
Unknown OBSERVATIONAL NCT04250129

SENTINEL LYMPH NODE BIOPSY AFTER NEOADJUVANT CHEMOTHERAPY (NEOSENTITURK)

IS SENTINEL LYMPH NODE BIOPSY WITH RADIOTHERAPY ALONE WITHOUT AXILLARY LYMPH NODE DISSECTION SAFE FOLLOWING NEOADJUVANT CHEMOTHERAPY IN INITIALLY CLINICALLY AXILLA POSITIVE PATIENTS: NEOSENTITURK-TRIAL/MF-18-03

Sponsor: Federation of Breast Diseases Societies

Conditions Sentinel Lymph Node
Updated 6 times since 2020 Last updated: Jan 30, 2020 Started: Jan 31, 2018 Primary completion: Dec 31, 2021 Completion: Jan 31, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04250129, this observational or N/A phase trial focuses on Sentinel Lymph Node and remains ongoing. Sponsored by Federation of Breast Diseases Societies, it has been updated 6 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshotRecruiting~Jan 2021 – ~Mar 2023 · 26 months · monthly snapshotRecruiting~Mar 2023 – ~Jul 2024 · 16 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotUnknown~Sep 2025 – present · 12 months · monthly snapshotUnknown

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown

    Status: Unknown Status → Unknown

  4. Mar 2023 — Jul 2024 [monthly]

    Unknown Status

    Status: Recruiting → Unknown Status

  5. Jan 2021 — Mar 2023 [monthly]

    Recruiting

▶ Show 1 earlier version

  1. Feb 2020 — Jan 2021 [monthly]

    Recruiting

    First recorded

Jan 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Federation of Breast Diseases Societies
Data source: Federation of Breast Diseases Societies

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations